Search Results
Your search for ,New matches 16916 pages
Showing 4251 - 4300Diversity in Clinical Trials Career Development Program
The Bristol Myers Squibb Foundation, the National Medical Fellowships, and the American Association for Cancer Research (AACR) recently announced the first group of 52 physicians selected for its Diversity in Clinical Trials Career Development Program. The 52 physicians selected by an independent...
Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective
The COVID-19 pandemic may have changed some aspects of health care forever. At the 2021 JADPRO Live Virtual event, a panel discussion focused on how several cancer centers faced challenges, and what changes the participants view as positive.1 JADPRO Live is an annual educational conference for...
WHO Launches a New Classification System for Pediatric Tumors, Incorporating Morphology, Immunohistochemistry Analysis, and Molecular Characteristics
A review article by Pfister et al published in Cancer Discovery summarizes the inaugural classification of pediatric tumors soon to be published by the International Agency for Research on Cancer as part of the new World Health Organization (WHO) Classification of Tumors series, including an online ...
Colorectal Cancer Screening: Preferences of Gastroenterologists and Primary Care Clinicians
Despite the availability of several effective screening tests, colorectal cancer screening rates remain below national goals. Although colonoscopy is the most often recommended screening method, a new study has found that the preferences of primary care clinicians have shifted toward noninvasive...
Study Examines Possible Clinical Trial Bias From Undisclosed Censoring
New research published by Wilson et al in JNCCN–Journal of the National Comprehensive Cancer Network found that only 59% of oncology clinical trials studied provided adequately defined rules for censoring. The researchers examined published randomized control trials supporting U.S. Food and Drug...
Carsten Utoft Niemann, MD, PhD, on CLL: Time-Limited Venetoclax and Ibrutinib for Patients With Relapsed or Refractory Disease
Carsten Utoft Niemann, MD, PhD, of Copenhagen University Hospital, discusses a primary analysis of the phase II Vision HO141 trial, which showed the feasibility of stopping and restarting ibrutinib and venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia who have...
Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab for Younger Patients With CLL
A study presented by Matthew S. Davids, MD, of Dana-Farber Cancer Institute, and colleagues at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 640) suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy may provide deep and lasting...
Global Burden of Cancer in Adolescent and Young Adult Patients in 2019
In a study reported in The Lancet Oncology, researchers working collectively as the Global Burden of Disease 2019 Adolescent and Young Adult Cancer Collaborators identified cancer incidence and mortality rates in 2019 among individual aged 15 to 39 years globally and according to country...
POLARIX: Pola-R-CHP vs R-CHOP for Previously Untreated Patients With DLBCL
The POLARIX study found patients with diffuse large B-cell lymphoma (DLBCL) had a significantly higher likelihood of survival without disease progression 2 years after receiving a new drug combination known as pola-R-CHP (polatuzumab vedotin-piiq with rituximab, cyclophosphamide, doxorubicin, and...
BELINDA Study: Second-Line Tisagenlecleucel Equivalent to Standard of Care for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
In an analysis of the phase III BELINDA trial presented by Bishop et al during the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract LBA-6), the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel was not found to improve event-free survival over the...
Outcomes With Adjuvant Chemoendocrine vs Endocrine Therapy in Node-Positive Breast Cancer and Association With 21-Gene Assay Recurrence Score
In an interim analysis of the phase III RxPONDER trial reported in The New England Journal of Medicine, Kevin Kalinsky, MD, and colleagues found that the addition of adjuvant chemotherapy to endocrine therapy did not improve invasive disease–free survival among women with hormone receptor–positive, ...
Study Examines Socioeconomic Status and Cervical Cancer Incidence in New York City
In a study reported in a research letter in JAMA Oncology, Cham et al found that cervical cancer incidence increased with decreasing socioeconomic status index scores across neighborhoods in New York City (NYC). Study Details The population-based, cross-sectional study included data on women...
HHS Secretary Becerra Names Lawrence Tabak, DDS, PhD, Acting Director of NIH
Health and Human Services Secretary Xavier Becerra recently announced that Lawrence A. Tabak, DDS, PhD, Principal Deputy Director of the National Institutes of Health (NIH), will serve as Acting Director of the NIH effective December 20, 2021. Earlier this year, current NIH Director Francis S....
ZUMA-7 Primary Analysis: Second-Line Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma
In the primary analysis of the phase III ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel led to a fourfold increase in event-free survival over the standard of care in the second-line treatment of relapsed or refractory large B-cell lymphoma, according to...
Study Identifies Factors for Severe COVID-19 Illness Among Patients With Acute Leukemia or MDS
In separate analyses of 257 patients with acute leukemia or myelodysplastic syndrome (MDS) who developed COVID-19 and are part of the American Society of Hematology (ASH) RC COVID-19 Registry for Hematology, both neutropenia and having active MDS or leukemia (vs being in remission) were found to...
Isatuximab/RVd Meets Primary Endpoint of MRD Negativity for Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma
For the first-line treatment of newly diagnosed, transplant-eligible patients with multiple myeloma, the achievement of measurable residual disease (MRD) negativity was significantly greater when the anti-CD38 monoclonal antibody isatuximab was added to the standard three-drug induction regimen of...
Ivosidenib/Azacitidine vs Azacitidine Alone in Patients With Newly Diagnosed IDH1-Mutated AML
In the phase III AGILE trial, the combination of ivosidenib and azacitidine was found to be superior in treating newly diagnosed patients with IDH1-mutated acute myeloid leukemia (AML) compared to azacitidine alone in terms of event-free survival, the study’s primary endpoint. The combination also...
Komal Jhaveri, MD, on Triple-Negative and Metastatic Breast Cancers: New Data on Neratinib, Fulvestrant, and Trastuzumab
Komal Jhaveri, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest updates from the SUMMIT trial, which explored the combinations of neratinib/fulvestrant/trastuzumab and neratinib plus trastuzumab, as well as fulvestrant alone. The combination regimens appeared to benefit patients...
Paolo Ghia, MD, PhD, on CLL: New Data on Treatment With Ibrutinib Plus Venetoclax
Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, discusses disease-free survival results from the measurable residual disease cohort of the phase II CAPTIVATE trial. This multicenter trial focuses on first-line ibrutinib plus venetoclax in patients...
TRANSFORM Trial: Lisocabtagene Maraleucel vs Standard of Care for Relapsed or Refractory Large B-Cell Lymphoma
An interim analysis of the TRANSFORM trial comparing the chimeric antigen receptor (CAR) T-cell immunotherapy lisocabtagene maraleucel to standard of care found that the CAR T-cell therapy significantly improved event-free survival for patients with large B-cell lymphoma that persisted or returned...
Activity of Mosunetuzumab in Pretreated Patients With Relapsed or Refractory Follicular Lymphoma
The bispecific antibody mosunetuzumab achieved deep and durable remissions as monotherapy in patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy, according to pivotal results of a phase I/II trial presented at the 2021 American Society of...
The National Cancer Act of 1971
On December 23, 1971, President Richard M. Nixon signed the National Cancer Act into law. At that time, cancer was the nation’s second leading cause of death; only about one of two people diagnosed with cancer survived at least 5 years—compared with two of three people diagnosed with the disease...
I’m Living—and Thriving—With Stage IV Non–Small Cell Lung Cancer
A diagnosis, in 2020, of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) was found accidentally. I was 55 at the time and in the best physical shape of my life. I had spent the previous year and a half on a diet and exercise regimen that had rendered me 35 pounds lighter and feeling...
Expect Questions on Use of Low-Dose Aspirin to Help Prevent Colorectal Cancer
Following a review of new data and additional analyses of previous data concerning colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) “concluded the evidence is inadequate that low-dose aspirin use reduces colorectal cancer incidence or mortality.”1 Consequently, a draft...
Update on the Role of Low-Dose Aspirin in Colorectal Cancer Prevention
Updating its 2016 recommendation on the use of aspirin to prevent cardiovascular disease and colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) issued a draft recommendation statement. It noted the potential harms of daily aspirin, with the most serious being bleeding in the...
The High Price of Pain
According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2019, nearly 247,000 people died from overdoses involving prescription opioids in the United States. According to the CDC, the problem can be broken into three waves. The first began with an increase in prescribing...
Reclaiming a Complicated Genius Who Pursued Cancer With Single-Minded Fury
The Nobel Laureate Otto Warburg was regarded as one of the most significant biochemists of the 20th century, whose exhaustive research led to an understanding of cancer that remains significant to this day. Warburg was also one of the most despised figures in his homeland of Nazi Germany. As a...
Erudition and Assessment on the Longest War in the Modern Era
A little after noon on December 23, 1971, President Richard Nixon entered the White House state dining room. Before 137 esteemed guests from government, science, and industry, he signed the landmark National Cancer Act. It was, in short, a national commitment to conquer cancer. President Nixon...
Early Operation With General Anesthesia
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
The History of Medical Oncology in Europe, 1955–1985
In part 1 of this two-part review, we looked at early pioneers in the field of medical oncology in Europe, as well as the development of international cooperative trials and the formation of European oncology societies (see related articles below). In part 2, we explore how the field of medical...
MSK Inaugurates New Center for Myelodysplastic Syndromes and Announces New Appointments
Memorial Sloan Kettering Cancer Center (MSK) recently acknowledged the commitment of the Edward P. Evans Foundation to inaugurate The Edward P. Evans Center for Myelodysplastic Syndromes (MDS) at MSK. With the grant of $5 million matched by institutional funds, MSK will establish the Edward P....
ACCC Presents 2021 Annual Awards for Significant Contributions to Oncology Care
The Association of Community Cancer Centers (ACCC) presented its 2021 Annual Awards at the its 38th National Oncology Conference, held virtually on November 9–10. The awards honor individuals who have made significant contributions to patient care, the practice of clinical care and research, and...
Mount Sinai Health System and BronxCare Health System Open Comprehensive Cancer Facility
Mount Sinai Health System, together with BronxCare Health System, recently held a ribbon-cutting to launch BronxCare Mount Sinai Comprehensive Cancer Care—a new, state-of-the-art comprehensive cancer facility in the Bronx. The new spacewill allow both health systems to bring their strengths...
Margaret Foti, PhD, MD (hc), Honored With 2021 Tara Withington Public Service Award
The American Association for Cancer Research (AACR) recently congratulated its Chief Executive Officer, Margaret Foti, PhD, MD (hc), on her recognition by the Society for Immunotherapy of Cancer (SITC) with its 2021 Tara Withington Public Service Award. According to the SITC, this award “honors an ...
Three Investigators Named Winners of MSK Cancer Center’s 2021 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three recipients of this year’s Paul Marks Prize for Cancer Research. The prize recognizes a new generation of leaders in cancer research who are making significant contributions to the understanding of cancer or are improving the...
Newer Cancer Therapies Offer Hope but Also May Confer Cardiac Risk
Since many different chemotherapeutic agents have been linked with cardiac adverse events, there is a growing need for strategies for the assessment and mitigation of treatment-induced cardiotoxicity. Moreover, the rapid rise of immunotherapies has added a new dimension to this clinical setting....
Mammen Chandy, MD, FRACP, FRACPA: A Pioneer in India’s Bone Marrow Transplantation Services
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with bone marrow transplant expert Mammen Chandy, MD, FRACP, FRACPA, Director of Tata Medical Center, in Kolkata, India. Dr. Chandy was instrumental in establishing the first sustained bone marrow...
Cancer Researcher and Biotech Founder Lewis Cantley, PhD, Joins Dana-Farber
Lewis Cantley, PhD, the cancer researcher best known for his discovery of the PI3K pathway and his groundbreaking work on cancer metabolism, will be joining the Dana-Farber Cancer Institute in February 2022. Dr. Cantley’s move from his current position as Director of the Sandra and Edward Meyer...
Mitchell D. Schnall, MD, PhD, Re-elected Group Co-Chair of the ECOG-ACRIN Cancer Research Group
The Principal investigator Committee of the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) re-elected Mitchell D. Schnall, MD, PhD, as the Group Co-Chair, a position he has held since the founding of the Group in 2012. Dr. Schnall will serve in this role from 2021 to 2031. Dr. Schnall co-leads the...
Tara O. Henderson, MD, MPH, to Lead Programs at UChicago Medicine, Chicagoland Children’s Health
Tara O. Henderson, MD, MPH, has been named the new Service Line Chief of Pediatric Cancer and Blood Diseases at the Chicagoland Children’s Health Alliance (CCHA), a collaboration between University of Chicago Medicine Comer Children’s Hospital, Advocate Children’s Hospital, and Pediatrics at...
Erratum
IN THE NOVEMBER 25, 2021, issue of The ASCO Post, a photo on page 1, in the article, “Shorter Course Radiation Therapy: A New Practice Standard After Prostatectomy,” was incorrectly identified as Mark K. Buyyounouski, MD, MS. We regret the error and apologize to Dr. Buyyounouski for the confusion....
The History of Medical Oncology in Europe, 1955–1985
Our goal with this review of the pivotal years of oncology in Europe is to acknowledge the tremendous contributions of the early leaders in the field and to help young investigators learn from the past to better cope with the inevitable challenges of today and tomorrow. “On ne connaît pas...
Help Test Performance Measures to Advance Oncology Quality of Care
ASCO is currently recruiting practices to participate in measures testing for a variety of efforts, including re-endorsing existing measures by the National Quality Forum (NQF). In addition to ensuring the highest level of quality care for individuals with cancer and advancing the specialty of...
COVID-19 Vaccine Requirements for Medicare, Medicaid Facilities, and Employers of 100 or More Staff Released
On November 4, 2021, the Centers for Medicare & Medicaid Services (CMS) issued an interim final rule requiring COVID-19 vaccination of eligible staff at health-care facilities that participate in the Medicare and Medicaid programs, and the Occupational Safety and Health Administration (OSHA)...
ASCO Releases New Guidelines on the Management of Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and CAR T-Cell Therapy
ASCO has released new recommendations for the management of adverse events related to two immunotherapy modalities with increasing application in cancer care—immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy. The recommendations were published as two separate...
Patients With Hormone Receptor–Positive Breast Cancer and Emergent ESR1 Mutations May Benefit From Early Switch to Fulvestrant/Palbociclib
Among patients with hormone receptor–positive breast cancer treated with an aromatase inhibitor plus palbociclib, those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to fulvestrant plus...
Jordan’s Queen Rania Presents King Hussein Awards for Cancer Research
Her Majesty Queen Rania Al Abdullah of Jordan honored recipients of the 2021 King Hussein Award for Cancer Research during ceremony held on November 14 by the King Hussein Cancer Foundation (KHCF). The event was conducted under the patronage of Their Majesties King Abdullah II and Queen Rania Al...
Update on the Incidence of NSCLC: Focus on Need to Implement Widescale Screening
Recent articles in JAMA Oncology focused on lung cancer and screening strategies. Apar Kishor Ganti, MD, MS, of the University of Nebraska Medical Center, Omaha, and colleagues provided updated data on non–small cell lung cancer (NSCLC) incidence, prevalence, and stage through 2017.1 Sylvia K....
Association of TP53 Gain-of-Function and Non–Gain-of-Function Mutations With Outcomes in Left-Sided vs Right-Sided Metastatic Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Pan et al found that overall survival was poorer among patients with metastatic right-sided vs left-sided colorectal cancer with TP53 mutations, driven by poorer outcomes in those with non–gain-of-function mutations, and that gain-of-function ...
Long-Term Outcomes From CheckMate 067: Nivolumab/Ipilimumab, Nivolumab, or Ipilimumab in Advanced Melanoma
In a 6.5-year update of the phase III CheckMate 067 trial reported in the Journal of Clinical Oncology, Jedd D. Wolchok, MD, PhD, FASCO, and colleagues provided long-term overall survival as well as melanoma-specific survival findings among patients with advanced melanoma who received nivolumab...
